Dual inhibition of CDK4 and CDK6 for pulmonary arterial hypertension

INDICATION: Hypertension

Patient sample and rat studies suggest dual inhibition of CDK4 and CDK6 could help treat pulmonary arterial hypertension (PAH). In lung samples from patients with idiopathic PAH, protein levels of CDK4 and CDK6 were higher than in samples from healthy volunteers. In two rat models of PAH, the dual CDK4/CDK6 inhibitor Ibrance palbociclib increased right ventricle function and decreased pulmonary vascular remodeling compared with vehicle. Next steps could include testing additional dual CDK4/CDK6 inhibitors in models of PAH...